Healthscopes offer for Symbion can only be good for API.
Healthscope plans to divest the pharmaceutical business to a private equity group.
This would be a sad day and would be the nail in the coffin for this pharmaceutical business which used to be the proud South Australian based international pharmaceutical business - FAULDING. The late Ed Tweddell and Peter Smedley have a lot to answer for.
I am sure the private equity group would already have plans to sell off the product portfolio, manufacturing business and pharmacetical wholesaling operations.
Thats why API went up today!!!!!!
API Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
